CATXNYSEPharmaceutical PreparationsUS GAAP · USD

Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a U.S.-based radiopharmaceutical company focused on developing targeted alpha therapies for cancer. The company combines clinical-stage drug development with owned and operated manufacturing facilities in the United States to support production, testing, and future commercialization of its program candidates.

Kysy yhtiöstä
Liikevoitto (EBIT)−114milj. USD
−25,0 %v/v
Nettotulos−103milj. USD
−30,1 %v/v
Vapaa kassavirta−95,2milj. USD
−31,0 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−125−100−75−50−25025milj. USD2020: 9,7 milj. USD2020: EBIT −3,5 milj. USD20202021: 10 milj. USD2021: EBIT −3,4 milj. USD20212022: 0,00 milj. USD2022: EBIT −8,7 milj. USD20222023: 1,4 milj. USD2023: EBIT −41 milj. USD20232024: EBIT −91 milj. USD20242025: EBIT −114 milj. USD2025−114
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Perspective Therapeutics, Inc.

Liiketoiminta

Osuus liikevaihdosta
Clinical-stage radiopharmaceutical programs90 %

Alpha-emitting oncology drug candidates in preclinical and clinical development.

Grant revenue10 %

Research support tied to work performed for the National Institutes of Health.

Asiakkaat

Perspective Therapeutics primarily serves cancer patients indirectly through hospitals, oncology centers, and clinical trial sites that administer its investigational therapies. Its current revenue base is tied to NIH-supported research work, while future commercial customers would include nuclear medicine centers and cancer treatment networks that use radiopharmaceutical products.

Clinical trial sites

Hospitals and research centers that enroll patients and administer investigational radiopharmaceuticals in Phase 1/2 studies.

Government research sponsor

The National Institutes of Health funds or supports research work that generates grant revenue.

Future oncology treatment centers

Cancer centers and nuclear medicine practices that could buy approved therapies for patient treatment.

Strategia

Perspective Therapeutics is building a vertically integrated radiopharmaceutical platform by advancing clinical assets, expanding manufacturing capacity, and preparing for future commercialization. Its strategy also includes adding personnel, protecting intellectual property, and pursuing additional program candidates through acquisition or in-license.

Advance clinical-stage radiopharmaceutical assetsLyhyt aikaväli

Clinical success is the main path to future product revenue and value creation.

Expand manufacturing and supply chain capacityKeskipitkä aikaväli

Radiopharmaceuticals require specialized production, handling, and distribution infrastructure.

Prepare for commercializationKeskipitkä aikaväli

Approved therapies will require manufacturing, distribution, and market access capabilities.

Maantiede

The company is headquartered in the United States and operates manufacturing and development activities across several U.S. metropolitan areas. Its facility footprint includes Somerset, New Jersey, and acquired or planned sites in Houston, Chicago, and Los Angeles, supporting future clinical and commercial supply in major U.S. cancer-treatment markets.

Riskit

The company faces the typical risks of clinical-stage biotechnology, including trial failure, regulatory delays, and the need for substantial external funding before product sales begin. Its specialized manufacturing strategy also creates execution risk around facility buildout, equipment validation, and reliable supply of radiopharmaceutical products.

Järjestetty vakavuuden mukaan
Clinical development failureKriittinen

The company’s value depends on proving safety and efficacy in human trials.

KohdistuuVMT01VMT-α-NETPSV359Other candidates
Regulatory approval riskKorkea

Even successful trials may not translate into marketing approval or timely labeling decisions.

Kohdistuu: All current and future program candidates

Financing and dilution riskKorkea

The business is pre-commercial and may need repeated capital raises to fund R&D and capex.

Kohdistuu: ATM equity program and future financing needs

Manufacturing and supply execution riskKorkea

Radiopharmaceutical production requires validated facilities, equipment, and tight logistics.

KohdistuuSomersetHoustonChicagoLos Angeles facilities
Kysy Clarifolta: Perspective Therapeutics, Inc.

Kirjanpito

Harkinnanvaraiset erät
Grant revenue recognition

Revenue currently comes from NIH-related work, so timing and scope of reimbursable work affect reported sales.

Vaikutus: Separates research support from future commercial product revenue

R&D expense capitalization versus expensing

Clinical trials, drug product costs, and delivery costs are expensed as incurred, affecting operating loss timing.

Vaikutus: Quarterly R&D volatility and comparability

Property, equipment, and lease accounting

Facility acquisitions and manufacturing equipment installation require capitalization, depreciation, and lease judgments.

Vaikutus: Affects balance sheet asset values and future expense recognition

Fair value of short-term investments

Cash and investment balances are important to funding runway and may include valuation-sensitive instruments.

Vaikutus: Can affect other income and liquidity presentation

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

Intensity Therapeutics, Inc

INTS · Biological Products, (No Diagnostic Substances)

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

PMV Pharmaceuticals, Inc.

PMVP · Pharmaceutical Preparations

BriaCell Therapeutics Corp.

BCTXZ · Pharmaceutical Preparations

Päivitetty: 24.9.2026